Marksans Pharma Steady Post-Q4 Earnings; Reaffirms ₹4,000 Cr FY28 Revenue Target

Synopsis: A quarter where EBITDA margins hit 22.8 percent and North America crossed Rs. 1,533 crore set the tone for Marksans Pharma’s post-Q4 FY26 earnings call, where management reaffirmed a Rs. 4,000 crore revenue target by FY28, guided for 15 to 20 percent topline growth in FY27, and disclosed two active M&A targets  one already in due diligence  expected to translate into transactions by calendar year 2027.

Marksans Pharma’s management presented a confident growth narrative on the back of a strong close to FY26, with North America delivering its best year yet, the UK and Europe recovering sharply in the second half, and Australia and New Zealand accelerating into branded prescription generics. The broader thesis, a mid-cap generics exporter building durable market presence across multiple regulated geographies  remains intact, even as a short-term input cost headwind tests margin stability entering FY27.

With a market capitalisation of Rs. 10,962.03 crore, the shares of Marksans Pharma Limited were last recorded at Rs. 242.04 per share, up 0.35 percent from its previous close of Rs.241.19. The stock trades at a P/E of 26.02.

North America remains the company’s largest and fastest-growing segment, contributing approx 52 percent of consolidated FY26 revenue at Rs. 1,533 crore  a 24 percent increase year-on-year, and a near-2.5x expansion from Rs. 635 crore just four years ago. The pace of SKU additions has been a key driver: 112 products were launched during FY26, with 51 additional SKUs already in the pipeline for FY27.

The Teva-acquired Goa facility is running at close to 50 percent utilisation, with management estimating that 40 to 50 percent of incremental growth can originate from this facility alone as additional dosage form capabilities are added through intra-facility capital expenditure.

Q1 FY27 Warning

FY26 EBITDA margins landed at 20.4 percent on a consolidated basis, with Q4 coming in notably stronger at 22.8 percent. Management attributed the full-year expansion to a better product mix, operating leverage, softening raw material costs in the second half, and sustained execution efficiencies, a combination that should be sustainable as long as input costs remain benign.

They are not, at least not yet. Management flagged inflationary pressure on petroleum-linked raw materials in Q1 FY27, with price escalations in the range of 20 to 30 percent, stemming from geopolitical and supply chain disruptions. The mitigation stance is deliberate rather than reactive: the company typically maintains five to six months of inventory cover on key materials, providing insulation for the immediate quarter.

On freight, logistics costs are running at approx two percentage points of revenue  materially lower than the Red Sea disruption period. Management also noted a partial offset from rupee depreciation on the export economics side.

Crucially, management declined to rush pricing renegotiations with buyers, citing uncertainty around whether crude-linked input costs would reverse quickly. The posture is explicitly one of observation rather than force majeure-style renegotiation. Despite all of this, FY27 EBITDA margin guidance was given as stable  “the same” as FY26’s 20-plus percent band  with management expressing comfort that the inventory buffer, product mix improvement, and FX tailwinds would collectively absorb the input shock.

FY27 and Beyond

Revenue growth guidance for FY27 was set at a conservative 15 to 20 percent, with the Rs. 4,000 crore target by FY28 reaffirmed. Management explicitly cautioned against annualising Q4 as a run rate, noting that Q1 is structurally the weakest quarter (winter season dependency affects several OTC categories), Q2 recovers, Q3 peaks, and Q4 is typically strong but not always the high point.

Europe beyond the UK is the next identified growth vector. Germany is being entered organically as the initial market, with broader European expansion via M&A also being actively explored. Management characterised Europe as a “cluster of markets” where each country has distinct regulatory and commercial norms, requiring either deep local knowledge or acquisition of established platforms. Separate from Europe, Canada is at the filing stage with small revenue contributions expected toward the end of the financial year, and commercial infrastructure is being built with deliberate capital discipline  only after approval timelines clarify.

M&A and Capital Allocation

The company holds Rs. 990 crore in net cash, a balance sheet position that gives it meaningful flexibility without compelling it toward dilutive deals. Management confirmed two active acquisition targets, with one already in due diligence. The deal philosophy emphasises geographic platform value over near-term earnings accretion, and management was explicitly conservative on valuations. CY2027 was given as the expected window for transactions to close. Shareholder returns, dividends or buybacks  were framed as secondary to M&A deployment in the capital allocation hierarchy.

Business Overview

Marksans Pharma Limited is a Mumbai-headquartered global pharmaceutical formulations company with a dominant focus on regulated markets  North America, the UK, Europe, and Australia  through both OTC and prescription generics. Its product categories span pain management, cough and cold, digestive remedies, cardiovascular, CNS, anti-diabetic, and oncology.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Marksans Pharma Steady Post-Q4 Earnings; Reaffirms ₹4,000 Cr FY28 Revenue Target appeared first on Trade Brains.